We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Read MoreHide Full Article
Key Takeaways
Moderna dosed the first U.S. participant in a phase I study of mRNA-4200 for advanced solid tumors.
MRNA-4200 targets seven shared tumor antigens and is being studied with checkpoint inhibitor therapy.
Moderna's Horizon 2 strategy includes mRNA-4200 and other early-stage oncology programs beyond vaccines.
Moderna (MRNA - Free Report) announced that it has dosed the first U.S. patient in a phase I study evaluating mRNA-4200, an investigational off-the-shelf, tumor-targeted cancer antigen therapy.
The study will assess the safety and tolerability of the candidate administered in combination with checkpoint inhibitor therapy in adults with advanced solid tumors. mRNA-4200 is Moderna’s third off-the-shelf cancer antigen therapy candidate and reflects its efforts to broaden the application of mRNA-based immunotherapies in oncology.
mRNA-4200 was developed in collaboration with Immatics (IMTX - Free Report) using its proprietary platforms. The candidate encodes seven shared tumor antigens designed to induce and expand T-cell responses across multiple tumor types.
Year to date, MRNA's shares have skyrocketed 114.1%, compared with the industry’s 2.5% growth.
To execute this strategy, the company has organized its business into three development horizons. Horizon 1 comprises the company's commercial products and late-stage pipeline assets, including the Merck (MRK - Free Report) -partnered personalized cancer therapy and investigational rare disease programs.
Horizon 2 focuses on early-stage clinical programs that include cancer antigen therapies, T-cell engagers and cell therapy enhancers. The study initiation on mRNA-4200, which is part of this horizon, illustrates Moderna's strategy of extending its proven mRNA technology beyond infectious diseases into oncology, reinforcing the company's objective of building a diversified portfolio of innovative therapies.
Horizon 3 consists of earlier-stage research programs that have not yet entered clinical development. These include in vivo CAR-T and CAR-M cell therapies, which could become the company's next-generation growth platforms.
View the Zacks #1 Rank List
Image: Bigstock
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Key Takeaways
Moderna (MRNA - Free Report) announced that it has dosed the first U.S. patient in a phase I study evaluating mRNA-4200, an investigational off-the-shelf, tumor-targeted cancer antigen therapy.
The study will assess the safety and tolerability of the candidate administered in combination with checkpoint inhibitor therapy in adults with advanced solid tumors. mRNA-4200 is Moderna’s third off-the-shelf cancer antigen therapy candidate and reflects its efforts to broaden the application of mRNA-based immunotherapies in oncology.
mRNA-4200 was developed in collaboration with Immatics (IMTX - Free Report) using its proprietary platforms. The candidate encodes seven shared tumor antigens designed to induce and expand T-cell responses across multiple tumor types.
Year to date, MRNA's shares have skyrocketed 114.1%, compared with the industry’s 2.5% growth.
Image Source: Zacks Investment Research
mRNA-4200 Supports MRNA's Long-Term Diversification Strategy
The initiation of the phase I mRNA-4200 study is closely aligned with Moderna's recently announced long-term strategy to diversify beyond its traditional vaccine business. The company plans to leverage its messenger RNA (mRNA) platform across multiple therapeutic areas.
To execute this strategy, the company has organized its business into three development horizons. Horizon 1 comprises the company's commercial products and late-stage pipeline assets, including the Merck (MRK - Free Report) -partnered personalized cancer therapy and investigational rare disease programs.
Horizon 2 focuses on early-stage clinical programs that include cancer antigen therapies, T-cell engagers and cell therapy enhancers. The study initiation on mRNA-4200, which is part of this horizon, illustrates Moderna's strategy of extending its proven mRNA technology beyond infectious diseases into oncology, reinforcing the company's objective of building a diversified portfolio of innovative therapies.
Horizon 3 consists of earlier-stage research programs that have not yet entered clinical development. These include in vivo CAR-T and CAR-M cell therapies, which could become the company's next-generation growth platforms.
MRNA’s Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1(Strong Buy) Rank stocks here.